

APPOINTMENT OF CHIEF FINANCIAL OFFICER

PERTH, Australia and SAN FRANCISCO, California – 7 July 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

PYC today announces the appointment of Mr. Thomas Ulmer as the Company's Chief Financial Officer.

Mr Ulmer has 20 years of international leadership experience across biotechnology, pharmaceuticals and healthcare. Most recently he served as Chief Financial Officer of Cell Therapies Pty Ltd and previously as Chief Executive Officer of PKG Health. Prior to this, Mr Ulmer was Chief Financial Officer of Immatix N.V. (NASDAQ: IMTX), where he played a key role in the company's NASDAQ listing and establishment as a US-listed biotechnology company. Earlier in his career he held senior finance leadership roles with Allergopharma and Merck Group.

Mr Ulmer holds an MBA from Justus Liebig University, Germany, and is a Fellow of CPA Australia.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact

investor@pyctx.com



¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>